Q2 2025 · 13F-HR
ARCH Venture Management, LLCholdings as filed
Filed 2025-08-14 · accession 0001012975-25-000444
$299.1M
Reported value
11
Positions
2025-06-30
Period end
The Brief · ARCH Venture Management, LLC · Q2 2025
AI · grounded in 13F
ARCH Venture Management, LLC established a new position in BEAM valued at $77.2M. The fund also initiated new stakes in VIR for $65.1M and MAZE for $50.6M. Additional new positions include RAPP at $42.4M, Verve Therapeutics Inc. at $22.6M, and LYEL at $16.1M. Total assets under management stand at $299.1M across 11 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 07373V105 | BEAM | BEAM THERAPEUTICS INC. | $77.2M | 25.8% | 4,540,132 | Common | NONE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC. | $65.1M | 21.8% | 12,916,663 | Common | NONE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC. | $50.6M | 16.9% | 4,120,053 | Common | NONE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC. | $42.4M | 14.2% | 3,728,738 | Common | NONE |
| 92539P101 | — | VERVE THERAPEUTICS INC. | $22.6M | 7.54% | 2,008,809 | Common | NONE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC. | $16.1M | 5.39% | 1,820,634 | Common | NONE |
| 29479A108 | ERAS | ERASCA INC. | $14.1M | 4.71% | 11,055,554 | Common | NONE |
| 38341P102 | GOSS | GOSSAMER BIO INC. | $9.9M | 3.31% | 8,055,916 | Common | NONE |
| 746964105 | QTTB | Q32 BIO INC. | $477,518 | 0.16% | 320,482 | Common | NONE |
| 91381U200 | UNBX | UNITY BIOTECHNOLOGY INC. | $385,950 | 0.13% | 1,004,817 | Common | NONE |
| 71902K402 | CERO | CERO THERAPEUTICS HOLDINGS INC. | $215,606 | 0.07% | 22,389 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.